<code id='F10951C94F'></code><style id='F10951C94F'></style>
      • <acronym id='F10951C94F'></acronym>
      <center id='F10951C94F'><center id='F10951C94F'><tfoot id='F10951C94F'></tfoot></center><abbr id='F10951C94F'><dir id='F10951C94F'><tfoot id='F10951C94F'></tfoot><noframes id='F10951C94F'>
      • <optgroup id='F10951C94F'><strike id='F10951C94F'><sup id='F10951C94F'></sup></strike><code id='F10951C94F'></code></optgroup>
        5. <b id='F10951C94F'><label id='F10951C94F'><select id='F10951C94F'><dt id='F10951C94F'><span id='F10951C94F'></span></dt></select></label></b><u id='F10951C94F'></u>
          <i id='F10951C94F'><strike id='F10951C94F'><tt id='F10951C94F'><pre id='F10951C94F'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / hotspot / leisure time      
           
     
           
      
          leisure time 
           
      
           
      
           
       2025-08-11 07:49:02 
   
      
           
      
           
                        
          leisure time  
          
                                   
                 
                                      author：hotspot   
                                        
                                      
                                      Page View：52266
                                  
                                    
          
                                   
          Nasdaq
          Mario Tama/Getty Images
          Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to become one of the few biotechs to go public this year.
          The company filed paperwork for an IPO with the Securities and Exchange Commission on Friday. It did not state how many shares it plans to sell or at what price.
          advertisement
          The biotech had begun planning for an IPO last year, STAT reported in June 2022. It raised $112 million in what would turn out to be a crossover round last October.
          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!					
          GET STARTED													Log In											
                      
                              
          
                                 Previous article：

                                
                                          Testing for cancer recurrence creates a new limbo for patients
                                
                            
          Next article：  
                                      
                                          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles